Effect of Hejie decoction on T cell immune state of chronic hepatitis B patients

Table 3 T lymphocyte subsets of responders and non-respond-ers in treatment group before and after treatment (mean ± SD)

		n	CD3 (%)	CD4 (%)	CD8 (%)
Responders	Pre-T	6	66.62 ± 8.86	35.10 ± 4.76b	34.02 ± 4.86b
	Post-T	6	66.80 ± 9.11	38.85 ± 8.85a	30.15 ± 5.82a
Non-responders	Pre-T	34	65.86 ± 9.08	34.62 ± 6.30b	34.17 ± 6.56b
	Post-T	34	66.09 ± 9.35	35.72 ± 8.70	33.85 ± 5.52
Normal		10	67.80 ± 8.65	39.07 ± 8.50	30.55 ± 5.52

n: Number; responders: Patients who had normal ALT and HBeAg and HBV DNA after treatment; non-responders: Pa-tients who had abnormal ALT, HBeAg and HBV DNA after treatment; normal: Normal group; Pre-T: Before treatment; Post-T: After treatment;

^aP < 0.05, vs before treatment in the same group,

^bP < 0.01, vs normal group.